The Company

Nutra Pharma Corporation, (OTC:NPHC), is an emerging biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, autoimmune, infectious diseases and pain. **Nutra Pharma Corporation's** current product portfolio includes proprietary therapeutic drugs targeted at autoimmune diseases as well as over-the-counter proprietary pharmaceuticals for the treatment of pain.

Therapeutic Drug Discovery

Nutra Pharma Corporation is currently developing a proprietary therapeutic protein product for the treatment of Multiple Sclerosis (MS): ***RPI-78M***.

- ***Nutra Pharma has completed pre-clinical and animal models for their MS drug and are preparing to move into pivotal Phase II trials.***
- ***Nutra Pharma Corporation's MS drug was granted Orphan Status by the FDA for the treatment of Pediatric Multiple Sclerosis.***

What is Multiple Sclerosis (MS)?

MS is an autoimmune disease whereby the immune system of the patients attacks the insulating sheath (myelin) of healthy nerves. This eventually leads to nerve damage, chronic fatigue and paralysis. Eventually, every MS patient becomes progressive and continues to worsen over time, regardless of medications.

The Failures of Existing Multiple Sclerosis (MS) Therapies

There have been no innovations in the treatment of MS in over 30 years. The available drugs primarily work by destroying the immune system of patients. This has the effect of slowing down the forward progression of the disease; not stopping it or reversing it – only slowing it down. Because these are immuno-suppressive drugs, they naturally have many side-effects, including: infection, PML (brain virus) and anaphylaxis. All of the drugs developed over the last three decades have been new versions of existing therapies.

What Makes RPI-78M Different?

RPI-78M is the first drug *ever tested* that has halted the forward progression of MS and reversed symptoms over time. In a published rat model of MS, the drug was found to reverse MS in the brains of rats and resolve 80% of existing lesions. In open-labelled studies, RPI-78M has been proven safe in over 300 study participants – even restoring ambulation and getting patients out of wheelchairs.

When compared to other biologic drugs, RPI-78M possesses several desirable properties, including:

- **It lacks measurable toxicity but is still capable of attaching to and affecting the target site on the cells. This means that patients cannot overdose.**
- **It displays no serious adverse side effects following years of investigations in humans and animals.**
- **Patients experience symptomatic improvements, usually within 6 months of therapy**
- **It is extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature.**
- **It is easy to administer as a daily intramuscular injection (mcg dosing).**



3-dimensional structure of RPI-78M

What Does this Mean for the MS Market and the Patients?

Nutra Pharma Corporation plans to conduct two clinical studies in MS:

The first will be a small study in adult patients with accompanying MRIs. The company expects to see in human brains what has already been demonstrated in animal models – a reversal of sclerosing lesions. If these results are obtained – it will be the first time that any therapeutic has shown disease modification of brain tissue.

The second trial will utilize the Orphan Designation in Pediatric MS to study the disease in patients under 16. There is currently no approved drugs to treat childhood MS. Under Orphan Designation, the study will be faster and less expensive than a usual Phase II study and result in exclusivity for the drug upon approval.

Next Steps and Licensing

Upon successful completion of either of the Phase II clinical studies, Nutra Pharma will seek a licensing partner to move into Phase III studies for eventual approval and distribution. The MS market is estimated to be at $20B annualized with license deals averaging 15-20% of drug sales.

If RPI-78M proves to work as already seen in the animal and open-labelled studies; it should take over the global market and change the lives of millions of Multiple Sclerosis patients.